Company / Working Capital
Aligos Therapeutics, Inc. Working Capital History
FY2020-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Working Capital
$61.6M
FY2025
5-year range
$40.4M / $165.5M
FY2021-FY2025
Trend
+52.5%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Working Capital has fluctuated over the past 6 years, ranging from $40M in FY2024 to $220M in FY2020.
Based on SEC 10-K filings.
$62M in FY2025 with a 5-year CAGR of -22.5%.
Declined from $117M to $62M over the past 2 years.
Working Capital over time
Growth rates
- 3-Year CAGR
- -15.0%
- 5-Year CAGR
- -22.5%
- 10-Year CAGR
- -
Key checks
Key Insights
- 5-year CAGR of -22.5%, indicating a declining trend.
- In FY2025, working capital increased 52.5% year-over-year.
- Peak working capital was recorded in FY2020.
- Lowest working capital in the period was in FY2024.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -8.07 (distress zone, below 1.8 threshold)
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Working CapitalValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $61.6M | +52.5% |
| FY2024 | $40.4M | -65.5% |
| FY2023 | $117.2M | +16.7% |
| FY2022 | $100.4M | -39.3% |
| FY2021 | $165.5M | -24.7% |
| FY2020 | $219.7M | - |
As of FY2025 · SEC 10-K · Updated Jun 24, 2026